Table 2 Oncological and medical history of patients positive for SARS-CoV-2
N = 118 | |
Past medical history | |
HTN | 31 (27) |
PVD/IHD/CVD | 9 (8) |
Diabetes mellitus | 14 (11) |
Obesity, BMI > 30, n (%) | 25 (21) |
Inflammatory/autoimmune | 7 (6) |
Smoking status | |
Current smoker | 36 (31) |
Ex-smoker | 51 (43) |
Never smoked | 12 (10) |
Unknown | 19 (16) |
Oncological history | |
Solid tumors, n = 97 | |
Disease status (in respect to last treatment) | |
SACT, palliative, n = 74 | |
CR/PR | 27 (28) |
SD | 24 (24) |
PD | 23 (24) |
SACT, neoadjuvant or radical CRT | 8 (8) |
Surgery ± adjuvant SACT | 15 (15) |
Treatment within 12 weeks | |
Systemic therapy | |
Chemotherapy | 43 (44) |
Small molecule inhibitor | 15 (15) |
Anti-PD-(L)1 ± anti-CTLA-4 | 14 (14) |
Endocrine therapy | 7 (6) |
No treatment | 5 (4) |
Local therapy | |
Surgery | 15 (13) |
Radiotherapy | 11 (10) |
Hematological malignancies, n = 21 | |
Diagnosis | |
Acute leukemia | 11 (52) |
Lymphoma | 6 (29) |
Myeloma | 4 (19) |
Disease status | |
MRD/CR | 5 (24) |
Partial remission | 7 (33) |
SD | 3 (14) |
PD/relapse/untreated acute presentation | 7 (33) |
Treatment within 12 weeks | |
Chemotherapy | 17 (81) |
Targeted therapy | 10 (48) |
Anti-CD20 therapy | 6 (29) |
CAR-T | 1 (5) |
Hematological stem cell transplant | |
Auto/allograft pre-COVID-19 | 6 (29) |
Auto/allograft post-COVID-19 | 2 (9) |
